Diagnosis and Prognosis for Aortic Aneurysm aNd Dissection in Anzhen(DPANDA) Study

Overview

The registry study aims to determine serial biomarkers to diagnosis and prognosis of aortic aneurysm/aortic dissection.

Full Title of Study: “Diagnosis and Prognosis for Aortic Aneurysm aNd Dissection in Anzhen”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Other
  • Study Primary Completion Date: December 31, 2022

Detailed Description

The study aims to investigate the role of candidate biomarkers in the diagnosis and prognosis of AA and AD. In the diagnosis part, we begin with a discovery phase where individually matched case-control study. Patients within each disease outcomes (i.e. AD, AMI, PE, AA without AD and healthy controls) are age and sex matched and retrospectively included.In the prognosis part of the study, patients with confirmed AA and AD are enrolled. The primary outcome is the all-cause mortality based on the death certificates. The secondary outcome is the in-hospital mortality according to the patients'medical records.

Arms, Groups and Cohorts

  • Top third of subjects based levels of selected biomarker.
  • Middle third of subjects based levels of selected biomarker.
  • Bottom third ofsubjects based levels of selected biomarker.

Clinical Trial Outcome Measures

Primary Measures

  • Dignosis of each participant
    • Time Frame: These data is collected from the cases’ medical record in an average of 6 month after the sample recruiting
    • Patients with Aneurysm/Dissection had image information from ultrasound cardiograms and computed tomography to confirm the final diagnosis. AMI if they had chest pain lasting >20 min, diagnostic serial ECG changes comprising new pathological Q waves or ST-segment and T-wave changes, and a plasma creatine kinase-MB elevation greater than twice the normal level or cardiac troponin I (cTnI) level greater than 0.1 ng/mL. Diagnosis of PE was confirmed by positive spiral computed tomography or pulmonary angiography, a high probability on ventilation perfusion scintigraphy, or a proximal deep vein thrombosis documented on compression ultrasonography or angiography.
  • Prognosis of each participant
    • Time Frame: These data is collected from the cases’ medical record or during follow-up visit at 2-4 years after discharge.
    • Prognosis information including all-cause mortality and in-hospital mortality.

Participating in This Clinical Trial

Inclusion Criteria

Retrospective

  • All patients who were referred to the surgical service for evaluation and management of aortic dissection were included. Perspective – Patients with initial suspicion of having AAD were perspectively enrolled. Exclusion Criteria:

Retrospective

  • Patients who received packed red blood cells, whole blood, or platelets less than 10 days before the blood sample was taken; – Patients with aortic trauma, pseudo aneurysm, history of heart failure, renal dysfunction, severe pulmonary diseases, or active cancer; – Patients who entered the hospital for checkups after surgery. Perspective – Patients in whom there is little or no suspicion of a life-threatening disease; – Patients with confirmed acute myocardial infarction,angina or pulmonary embolism – The symptoms were clearly not related to AD (e.g. pleurisy, pneumonia, acute abdominal diseases).

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Investigator Details

  • Lead Sponsor
    • Beijing Institute of Heart, Lung and Blood Vessel Diseases
  • Collaborator
    • Beijing Luhe Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Yuan Wang, PhD, 86-010-64456721, wangyuan980510@163.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.